After finishing her studies in Biomedical Chemistry at the University of Mainz, Germany, Dr. M. Bastian started her PhD studies at the University of Groningen in 2009. Working in the group of Nobel laureate Prof. Dr. Ben Feringa, she gained experience in rout scouting and complex total synthesis of natural product inspired molecular structures.
In 2014, she decided to perform her postdoctoral studies in the group of Prof. Dr. S. Mobashery at the University of Notre Dame in the United States. There, Dr. Bastian was involved in drug development in different pre-clinical stages, i.e. hit-finding, hit-to-lead optimization including in vitro and in vivo studies. She published her successful work in multiple scientific journals. Before she joined AGILeBiotics as Chief Scientific Officer in 2017, Dr. M. Bastian worked at Syncom BV as Research Scientist. At AGILeBiotics, Dr. M. Bastian is taking the responsibility in various lead-optimization projects developing the next generation antibiotic against multidrug-resistant pathogens.